Home » Topics » BioWorld Science

BioWorld Science
RSS

Safety and immunogenicity of BNT-162b1 confirmed in phase I study in Chinese adults

July 13, 2021

Uproleselan studied with venetoclax and azacitidine for older or unfit patients with AML

July 13, 2021

Vaccibody and Adaptive Biotechnologies sign license agreement on SARS-CoV-2 T-cell epitopes

July 13, 2021

Patients dosed in phase I/II trial of topical RECCE-327 for infected burn wounds

July 13, 2021

Immunic presents new preclinical and clinical data for IMU-935

July 13, 2021

Qixleef phase II protocol modifications approved

July 13, 2021

Prokineticin-2 as therapeutic target for prevention of neuronal death

July 13, 2021

Aptorum reports further interim phase I data on ALS-4

July 13, 2021

Identification of antivirulence compound ANT-3273 for P. aeruginosa infection

July 13, 2021

Dosing begins in phase I study of CB-010 in B-cell NHL

July 13, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 6, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...
Bio Korea 2026: US policy risks shift to execution framework
BioWorld
Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...
Latus Bio series A financing supports early-stage programs
BioWorld Science
Latus Bio Inc. has closed a $97 million series A financing to support its broad therapeutics pipeline based on novel AAV capsid variants. Proceeds from the...